Paper Review Records
All Paper Review Records
25 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
116
days
Differential in vivo tyrosine kinase inhibitor sensitivities of pediatric ABL‐class Ph‐like B‐acute lymphoblastic leukemia
Authors
Ritul Sharma; Jackson K. Dardis; Huong Anh Mai; Camilo Arenas Merizalde; Cesca van de Ven; Diego A. Bárcenas López; Shubhmita Bhatnagar; Andishe Attarbaschi; Judith M. Boer; Monique L. den Boer; Sarah K. TasianShow moreShow less
Affiliations
1. Division of Oncology and Center for Childhood Cancer Research Children's Hospital of Philadelphia Philadelphia Pennsylvania United States; 2. Princess Máxima Center for Pediatric Oncology Utrecht The Netherlands; 3. Department of Pediatric Hematology and Oncology St Anna Children's Hospital Vienna Austria; 4. Center for Translational Immunology, University Medical Center Utrecht The Netherlands; 5. Department of Pediatrics University of Pennsylvania School of Medicine Philadelphia Pennsylvania United States; 6. Abramson Cancer Center, University of Pennsylvania School of Medicine Philadelphia Pennsylvania United StatesShow moreShow less
163
days
Targeted proteomics reveal histiocytosis‐associated neurodegeneration signatures
Authors
Egle Kvedaraite; Magda Lourda; Johannes Bastiaan Munting; Matthias Papo; Martin Jädersten; Yoko Shioda; Kenichi Sakamoto; Daniel Martín Muñoz; Panagiotis Andriopoulos; Francesco Pegoraro; Evaldas Laurencikas; Ingrid Kühnle; Joakim Wille; Leonie Naeije; Helena Olkinuora; Indranil Sinha; Daniel W. Hagey; Selma Olsson‐Åkefeldt; Fleur Cohen‐Aubart; Gustaf Österlundh; Mattias Svensson; Ahmed Idbaih; Fredrik Piehl; Kaj Blennow; Henrik Zetterberg; Tatiana Greenwood von Bahr; Désirée Gavhed; Akira Morimoto; Julien Haroche; Jan‐Inge HenterShow moreShow less
Affiliations
1. Department of Pathology and Cancer Diagnostics Karolinska University Hospital Stockholm Sweden; 2. Unit of Molecular Neurobiology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet Stockholm Sweden; 3. The Systems Virology Laboratory, Department of Laboratory Medicine, Division of Clinical Microbiology, Karolinska Institutet Stockholm Sweden; 4. Internal Medicine Department 2, French National Referral Center for Histiocytoses Sorbonne University, Assistance Publique–Hôpitaux de Paris, Pitié‐Salpêtrière Hospital Paris France; 5. Department of Medicine Huddinge, Center for Hematology and Regenerative Medicine, Karolinska Institutet Stockholm Sweden; 6. Department of Hematology Karolinska University Hospital Stockholm Sweden; 7. Children's Cancer Center, National Center for Child health and Development Tokyo Japan; 8. Department of Pediatrics Shinshu University School of Medicine Matsumoto Japan; 9. Department of Neuroradiology and Pediatric Radiology Karolinska University Hospital Solna Stockholm Sweden; 10. Department of Experimental and Clinical Medicine University of Florence Florence Italy; 11. Department of Hematology and Oncology, Meyer Children's Hospital IRCCS Florence Italy; 12. Childhood Cancer Research Unit, Department of Women's and Children's Health, Karolinska Institutet Stockholm Sweden; 13. Division of Pediatric Hematology and Oncology Göttingen University Medical Center Göttingen Germany; 14. Childhood Cancer Center Skåne University Hospital Lund Sweden; 15. Princess Máxima Center for Pediatric Oncology Utrecht the Netherlands; 16. Division of Pediatric Hematology‐Oncology and Stem Cell Transplantation, New Children's Hospital Helsinki University Hospital Helsinki Finland; 17. Department of Laboratory Medicine, Division of Biomolecular and Cellular Medicine, Karolinska Institutet Stockholm Sweden; 18. Department of Pediatrics, The Queen Silvia Children's Hospital University of Gothenburg Gothenburg Sweden; 19. Department of Medicine Huddinge, Center for Infectious Medicine, Karolinska Institutet Karolinska University Hospital Stockholm Sweden; 20. Sorbonne Université, AP‐HP, Institut du Cerveau ‐ Paris Brain Institute ‐ ICM, Inserm, CNRS Hôpitaux Universitaires La Pitié Salpêtrière ‐ Charles Foix, Service de Neuro‐Oncologie‐Institut de Neurologie Paris France; 21. Department of Neurology Karolinska University Hospital Stockholm Sweden; 22. Neuroimmunology Unit, Center for Molecular Medicine, Karolinska Institutet Stockholm Sweden; 23. Department of Clinical Neuroscience, Karolinska Institutet Stockholm Sweden; 24. Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy University of Gothenburg Mölndal Sweden; 25. Clinical Neurochemistry Laboratory Sahlgrenska University Hospital Gothenburg Sweden; 26. Institute of Neurology University College London London UK; 27. Pediatric Oncology, Astrid Lindgren Children's Hospital Karolinska University Hospital Stockholm Sweden; 28. Division of Pediatrics, Showa Inan General Hospital Komagane JapanShow moreShow less
138
days
3D ex vivo platform for high‐throughput immunotherapy screening in relapsed/refractory lymphoma patients
Authors
Fabien Gava; Paul Marcoux; Neus Serrat; Pauline Gravelle; Sonia Quertinmont; Marie Tosolini; Carla Faria; Juan G. Valero; Christina Schniederjohann; Cathy Quelen; Fanny Bouquet; Catia Fonseca; Sylvia Herter; Laura C. Deak; Ron McCord; Eugene Chiang; Peter‐Martin Bruch; Loïc Ysebaert; Patricia Pérez‐Galán; Camille Laurent; Christine BezombesShow moreShow less
Affiliations
1. Univ Toulouse, INSERM, CRCT Toulouse France; 2. Institut Claudius Regaud ‐ IUCT‐Oncopole, imCORE site Toulouse France; 3. Laboratoire d'Excellence ‘TOUCAN‐2' Toulouse France; 4. Institut Carnot Lymphome CALYM Pierre‐Bénite France; 5. Department of Pathology IUCT‐Oncopole Toulouse France; 6. Fundació Clínic per a la Recerca Biomèdica—Institut d'Investigacions Biomèdiques August Pi i Sunyer Barcelona Spain; 7. Centro de Investigación Biomédica en Red‐Oncología (CIBERONC) Madrid Spain; 8. Oncology Department UNIL‐CHUV Bernhard Gentner laboratory, Agora Research Center Lausanne Switzerland; 9. Department of Hematology Hospital Clínic Barcelona Spain; 10. Department of Hematology, Oncology and Clinical Immunology Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University Düsseldorf Düsseldorf Germany; 11. Center for Integrated Oncology Aachen‐Bonn‐Cologne‐Düsseldorf (CIO ABCD) Düsseldorf Germany; 12. Molecular Medicine Partnership Unit (MMPU) Heidelberg Germany; 13. Department of Medicine V Heidelberg University Hospital Heidelberg Germany; 14. F.Hoffmann‐La Roche Zurich Switzerland; 15. Roche Pharma Research and Early Development Roche Innovation Center Zürich Schlieren Switzerland; 16. Genentech San Francisco California USA; 17. Department of Hematology IUCT‐Oncopole Toulouse FranceShow moreShow less
108
days
Increased risk of secondary malignancies after autologous transplantation in R/R follicular lymphoma: Long‐term results from FIL‐FLAZ12 Phase III trial
Authors
Rita Tavarozzi; Andrea Evangelista; Manuela Zanni; Chiara Consoli; Alessandra Tucci; Barbara Botto; Silvia Bolis; Pietro Lauzzana; Vittorio Ruggero Zilioli; Benedetta Puccini; Annalisa Arcari; Vincenzo Pavone; Gloria Margiotta‐Casaluci; Monica Tani; Federica Cavallo; Antonio Pinto; Chiara Ghiggi; Domenico Pastore; Paolo Corradini; Andrés José María Ferreri; Angelo Palmas; Caterina Patti; Francesca Re; Fabio Benedetti; Giuseppe Milone; Stefano Luminari; Elsa Pennese; Elisa Bossi; Carola Boccomini; Antonella Anastasia; Chiara Bottelli; Donato Mannina; Samantha Pozzi; Catello Califano; Luca Arcaini; Flavio Falcinelli; Giuseppe Pietrantuono; Ilaria Del Giudice; Sara Usai; Jacopo Olivieri; Filippo Gherlinzoni; Attilio Olivieri; Tommasina Perrone; Fabrizio Pomponi; Giovannino Ciccone; Umberto Vitolo; Marco LadettoShow moreShow less
Affiliations
1. Department of Translational Medicine University of Eastern Piedmont Novara Italy; 2. SCDU of Hematology AOU SS Antonio e Biagio e Cesare Arrigo Alessandria Italy; 3. Unit of Clinical Epidemiology AOU Città Della Salute E Della Scienza Di Torino and CPO Piemonte Turin Italy; 4. Department of Molecular Biotechnology and Health Sciences, Hematology Division University of Torino Turin Italy; 5. Department of Hematology Spedali Civili Brescia Italy; 6. Struttura Complessa Ematologia AOU Città della salute e della scienza di Torino Turin Italy; 7. Division of Haematology SC Ematologia Fondazione Irccs San Gerardo dei Tintori Monza Italy; 8. Division of Hematology, Clinica Ematologica, Centro Trapianti e Terapie Cellulari Carlo Melzi DISM, Azienda Ospedaliero Universitaria S. M. Misericordia Udine Italy; 9. Division of Haematology ASST Grande Ospedale Metropolitano Niguarda Milan Italy; 10. Department of Haematology University of Florence Florence Italy; 11. Division of Hematology AUSL of Piacenza Piacenza Italy; 12. Hematology Unit Ospedale Guglielmo da Saliceto Piacenza Italy; 13. SC of Hematology A. O. C. Panico‐U. O. C Ematologia e Trapianto Tricase Italy; 14. Division of Hematology AOU Maggiore della Carità di Novara Novara Piedmont Italy; 15. Hematology Unit, Department of Oncology and Hematology “Santa Maria delle Croci” Hospital Ravenna Italy; 16. Department of Hematology Istituto Nazionale Tumori Istituto di Ricovero e Cura a Carattere Scientifico “Fondazione G Pascale” Naples Italy; 17. IRCCS Azienda Ospedaliera Metropolitana Divisione di Ematologia e Terapie Cellulari Genova Italy; 18. Division of Hematology Ospedale Antonio Perrino Brindisi Italy; 19. Division of Hematology IRCCS Istituto Nazionale Tumori Milan Italy; 20. Lymphoma Unit IUniversity Vita‐Salute San Raffaele Milan Italy; 21. Strategic Program on Lymphomas IRCCS San Raffaele Scientific Institute Milan Italy; 22. Unità di Ematologia e Trapianto di Midollo Osseo, San Francesco Hospital Nuoro Italy; 23. SCDU of Hematology “Villa Sofia – Cervello” Hospital Palermo Italy; 24. Department of Hematology A. O. U. di Parma Parma Italy; 25. Department of Medicine, Section of Hematology and Bone Marrow Transplant Unit University of Verona Verona Italy; 26. Division of Hematology and Program for Hematopoietic Transplantation Azienda Ospedaliera Policlinico Vittorio Emanuele Catania Italy; 27. Hematology Azienda Unità Sanitaria Locale IRCCS of Reggio Emilia Reggio Emilia Italy; 28. SCDU of Hematology Presidio Ospedaliero Pescara Pescara Italy; 29. Hematology Unit Papardo Hospital Messina Messina Italy; 30. Dipartimento di Scienze Mediche e Chirurgiche Materno‐Infantili e dell'Adulto Università di Modena e Reggio Emilia Modena Italy; 31. Hematology Hospital “Andrea Tortora” Pagani Italy; 32. Department of Molecular Medicine University of Pavia Pavia Italy; 33. Division of Hematology Fondazione IRCCS Policlinico San Matteo Pavia Italy; 34. Hematology and Bone Marrow Transplantation Azienda Ospedaliera Di Perugia Perugia Italy; 35. IRCCS CROB Referral Cancer Center of Basilicata Rionero in Vulture Italy; 36. Hematology, Department of Translational and Precision Medicine Sapienza University of Rome Rome Italy; 37. Unit of Hematology and Bone Marrow Transplant AO Brotzu ‐ Ospedale Oncologico Businco Cagliari Italy; 38. Clinica Ematologica Azienda Sanitaria Universitaria Friuli Centrale Udine Italy; 39. Division of Hematology Ca' Foncello Hospital Treviso Italy; 40. SCDU of Hematology Ospedale Regionale delle Marche Ancona Italy; 41. Department of Emergency and Organ Transplantation D. E. T. O., Hematology Section University of Bari Bari Italy; 42. Division of Hematology U.O.C. di Ematologia ‐ AULSS8 Berica Vicenza Italy; 43. Hematology IRCCS Candiolo Cancer Institute Turin ItalyShow moreShow less
251
days
Venetoclax plus azacitidine, low‐dose cytarabine, aclarubicin, and G‐CSF (VA‐CAG regimen) for newly diagnosed young patients with acute myeloid leukemia: A prospective, multicenter, single‐arm Phase II clinical trial
Authors
Xiaoping Li; Qiurong Zhang; Xiaoyan Li; Lin Liu; Yonglin Shen; Yu Li; Lihui Peng; Chaoyang Zhou; Chie Qiu; Zhongtao Yuan; Shiqian Hou; Youcheng Wang; Lihua Zhang; Jingqiong Li; Liang Zhao; Qiuyuan Tang; Zucong Chen; Jing Feng; Xuejuan Zhang; Guoxiu Bao; Kui Zhang; Renpeng Zhang; Shiqi Li; Yingnian Chen; Jianhua Rao; Yancheng Dong; Dingsong Zhang; Yueyuan Wang; Aifang Li; Xi Ye; Lei Lei; Jiao Chen; Sufen Xu; Yanling Jin; Chaoen Zheng; Yang Liang; Sanbin WangShow moreShow less
Affiliations
1. Department of Haematology 920th Hospital of Joint Logistics Support Force Kunming China; 2. Department of Haematology The First Affiliated Hospital of Dali University Dali China; 3. Department of Haematology The People's Hospital of Baoshan Baoshan China; 4. Department of Haematology and Oncology The Southern Central Hospital of Yunnan province Gejiu China; 5. Department of Haematology The People's Hospital of Chuxiong Chongxiong China; 6. Department of Haematology The Northeast Yunnan Center Hospital Zhaotong China; 7. Department of Haematology The People's Hospital of Yuxi City Yuxi China; 8. Department of Haematology and Oncology The People's Hospital of Lijiang Lijiang China; 9. Department of Haematology Xishuangbanna Dai Autonomous Prefecture People's Hospital Jinghong China; 10. Department of Haematology The People's Hospital of Dehong Prefecture Mangshi China; 11. Department of Haematology Dali Bai Autonomous Prefectue People's Hospital Dali China; 12. Department of Haematology The Second People's Hospital of Qujing Qujing China; 13. Department of Haematology The First People's Hospital of Zhaotong Zhaotong China; 14. Department of Haematology and Oncology The People's Hospital of Lincang Lincang China; 15. Department of Haematology Qujing Central Hospital of Yunnan Province Qujing China; 16. Department of Haematology and Rheumatism Immunity The People's Hospital of Puer Puer China; 17. Department of Hematological Oncology, State Key Laboratory of Oncology in South China Guangdong Provincial Clinical Research Centre for Cancer, Sun Yat‐sen University Cancer Center Guangzhou ChinaShow moreShow less
12
days
Isn't it ironic? Confessions of a pregnant, iron deficient hematologist
Authors
Lauren E. MerzShow moreShow less
Affiliations
1. Division of Hematology/Oncology, Department of Medicine University of Michigan Ann Arbor MI USAShow moreShow less
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
Client
I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?
CrushSCI
Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.
- Suggested title
- Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment
- Database shortlist
- Environmental Technology & Innovation
SampleLatest 5 valid paper samples from 2026
Average review62 days
Median65 days